title: [Is adjuvant chemotherapy of colon cancers (Dukes C; TxN+) regarded as standard today?].
authors.affiliation: Chirurgische Universitätsklinik, Freiburg.
authors.forename: E
authors.initials: E
authors.lastname: Farthmann
authors.forename: C
authors.initials: C
authors.lastname: Herfarth
authors.forename: U
authors.initials: U
authors.lastname: Laffer
authors.forename: F
authors.initials: F
authors.lastname: Harder
authors.forename: P M
authors.initials: PM
authors.lastname: Schlag
authors.forename: H
authors.initials: H
authors.lastname: Wilke
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D003131:Combined Modality Therapy; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007978:Levamisole / Q000008:administration & dosage / Q000009:adverse effects; D009367:Neoplasm Staging; D015996:Survival Rate
chemical_list: D007978:Levamisole; D005472:Fluorouracil
vernacular_title: Ist die adjuvante Chemotherapie von Kolonkarzinomen (Dukes C; TxN+) heute als Standard anzusehen?